AstraZeneca Calquence approved in China for chronic lymphocy

Cambridge: AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic...

Related Keywords

Japan , China , Chinese , Dave Fredrickson , Li Jianyong , National Medical Products Administration , Astrazeneca , Jiangsu Province , Executive Vice President , Oncology Business Unit , Astrazeneca News , Calquence , Acalabrutinib , Lymphocytic Leukaemia , Rituximab , Bendamustine , Professor Li Jianyong , ,